Clinical Trial Update: Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating adjuvant tislelizumab plus lenvatinib for patients at high risk of hepatocellular carcinoma recurrence after curative resection or ab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Guangxi Medical University | Conditions: Hepatocellular Carcinoma, Recurrence | Phase 3 | Status: UNKNOWN